Finally, since we, and others,have demonstrated that RIG-I activation in cancer cells can be importantto therapeutic responses,16,28,29 we also tested the activity of SLR-LNPs in B16.F10 melanoma andEO771 breast cancer cells, again demonstrating that SLR-LNPs increasedexpression of cytokines associated with RIG-I activation relativeto controls (Figure S1C,D). This evidence concerns the gene RIGI and breast carcinoma.